The relevant distinction between “progression” in ovarian cancer drug trials and the clinical decision to change therapy - Markman (very short abstract) Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, October 09, 2010

The relevant distinction between “progression” in ovarian cancer drug trials and the clinical decision to change therapy - Markman (very short abstract)



abstract: "It is rational to suggest that the decision to alter treatment in advanced ovarian cancer should be based on the totality of evidence that the disease is worsening, on patient tolerability of the therapy, and on a determination that the current regimen is providing no benefit or unacceptably limited benefit to the specific individual. Knowledge of an objective measure of “progression” should play an important, but not a singular, role."

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.